Elisabet Lindqvist
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Elisabet Lindqvist has a total of 93 co-authors. Here are the top co-authors by number of shared publications:
- Elisabeth Mogard
Department of Clinical Sciences Lund, Rheumatology, Lund University, Lund, Sweden
13 shared publications - Ann Bremander
The Danish Center for Expertise in Rheumatology, Danish Hospital for Rheumatic Diseases, University Hospital of Southern Denmark, Sønderborg, Denmark
9 shared publications - Tor Olofsson
Department of Clinical Sciences Lund, Rheumatology, Lund University, Lund, Sweden
8 shared publications - Ingrid Larsson
Department of Health and Care, School of Health and Welfare, Halmstad University, Halmstad, Sweden
6 shared publications - Johan Karlsson Wallman
Department of Clinical Sciences Lund, Rheumatology, Skåne University Hospital, Lund University, Lund, Sweden
6 shared publications - Mats Geijer
Department of Radiology, Sahlgrenska University Hospital, Gothenburg, Sweden
5 shared publications
Latest Publications
- Open Access
- 10 September 2026
- Published by Elsevier in EULAR Rheumatology Open
- Vol. 2 (3)
Learning to live with RA as an unwelcome companion—patients’ experiences after 1 to 2 years of DMARD treatment
- 10 September 2026
- Published by Elsevier in EULAR Rheumatology Open
- Vol. 2 (3)
Open AccessLearning to live with RA as an unwelcome companion—patients’ experiences after 1 to 2 years of DMARD treatment
- Open Access
- 23 May 2026
- Published by Springer Nature in Rheumatology International
- Vol. 46 (6) , 99
Axial spondyloarthritis patients with comorbid fibromyalgia feel worse, work less and more often try multiple biological therapies: results from a population-based, cross-sectional study investigating the discriminative capacity of pressure algometry
To estimate prevalence and associated factors of comorbid fibromyalgia in axial spondyloarthritis (axSpA), and to explore discriminative capacity (for discerning fibromyalgia) of algometry-assessed pain sensitivity measures. AxSpA patients from the population-based SPARTAKUS cohort evaluated for fibromyalgia (1990 ACR criteria) were included ( n = 243; r-axSpA/nr-axSpA = 165/78). Factors associated with fibromyalgia were cross-sectionally analyzed by logistic/linear regression, and discriminative potential of algometry-assessed measures estimated by ROC-curve analysis. A fibromyalgia prevalence of 9% was demonstrated, with a higher frequency in female than male patients (17%/2%;adjusted p < 0.001) and more than a doubling in frequency per 5-unit BMI increase (adjusted p < 0.002). Fibromyalgia was associated with several disease/work outcomes, including higher disease activity, lower quality-of-life, and less employment although without association to swollen joints/CRP. Additionally, patients with (versus without) fibromyalgia had higher bDMARD exposure (19%/5% had tried ≥ 3 bDMARDs; adjusted p = 0.009), and were more often on opioids (62%/16%;adjusted p < 0.001). Algometry-assessed measures displayed a sensitivity/specificity of 79%/70% (pain threshold) and 71%/83% (pain tolerance) for fibromyalgia differentiation (positive/negative predictive values 16%/99% and 23%/98%, respectively). Fibromyalgia is a frequent comorbidity in axSpA, more common in female patients/patients with higher BMI, and associated with worse levels of patient-reported disease/work outcomes. Our findings highlight the challenge of assessing axSpA disease activity when fibromyalgia is present and suggest a role for algometry as a complementary, evaluator-independent assessment tool, potentially useful for fibromyalgia rule-out but less so for rule-in. The results further suggest that fibromyalgia may be associated with DMARD overtreatment, reflecting a need for earlier and more precise targeting.
- 23 May 2026
- Published by Springer Nature in Rheumatology International
- Vol. 46 (6) , 99
Open AccessAxial spondyloarthritis patients with comorbid fibromyalgia feel worse, work less and more often try multiple biological therapies: results from a population-based, cross-sectional study investigating the discriminative capacity of pressure algometry
To estimate prevalence and associated factors of comorbid fibromyalgia in axial spondyloarthritis (axSpA), and to explore discriminative capacity (for discerning fibromyalgia) of algometry-assessed pain sensitivity measures. AxSpA patients from the population-based SPARTAKUS cohort evaluated for fibromyalgia (1990 ACR criteria) were included ( n = 243; r-axSpA/nr-axSpA = 165/78). Factors associated with fibromyalgia were cross-sectionally analyzed by logistic/linear regression, and discriminative potential of algometry-assessed measures estimated by ROC-curve analysis. A fibromyalgia prevalence of 9% was demonstrated, with a higher frequency in female than male patients (17%/2%;adjusted p < 0.001) and more than a doubling in frequency per 5-unit BMI increase (adjusted p < 0.002). Fibromyalgia was associated with several disease/work outcomes, including higher disease activity, lower quality-of-life, and less employment although without association to swollen joints/CRP. Additionally, patients with (versus without) fibromyalgia had higher bDMARD exposure (19%/5% had tried ≥ 3 bDMARDs; adjusted p = 0.009), and were more often on opioids (62%/16%;adjusted p < 0.001). Algometry-assessed measures displayed a sensitivity/specificity of 79%/70% (pain threshold) and 71%/83% (pain tolerance) for fibromyalgia differentiation (positive/negative predictive values 16%/99% and 23%/98%, respectively). Fibromyalgia is a frequent comorbidity in axSpA, more common in female patients/patients with higher BMI, and associated with worse levels of patient-reported disease/work outcomes. Our findings highlight the challenge of assessing axSpA disease activity when fibromyalgia is present and suggest a role for algometry as a complementary, evaluator-independent assessment tool, potentially useful for fibromyalgia rule-out but less so for rule-in. The results further suggest that fibromyalgia may be associated with DMARD overtreatment, reflecting a need for earlier and more precise targeting.
- Open Access
- 4 March 2026
- Published by Elsevier in EULAR Rheumatology Open
- Vol. 2 (1) , 306-313
Patients’ experiences of managing lifestyle habits following a rheumatoid arthritis diagnosis
- 4 March 2026
- Published by Elsevier in EULAR Rheumatology Open
- Vol. 2 (1) , 306-313
Open AccessPatients’ experiences of managing lifestyle habits following a rheumatoid arthritis diagnosis
- Open Access
- 21 October 2025
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 27 (1) , 1-9
Gut inflammation is associated with structural spinal damage in axial spondyloarthritis – results from the observational SPARTAKUS cohort
Background: In axial spondyloarthritis (axSpA), 5–10% of patients have comorbid inflammatory bowel disease (IBD). Beyond that, 50–60% display histologic inflammation in ileum/colon biopsies, and fecal calprotectin (F-calprotectin) is elevated in relation to healthy controls. Prior studies have shown such, often subclinical, gut inflammation in axSpA to be associated with more active disease, as measured by clinical indices as well as magnetic resonance imaging – both known risk factors for structural spinal damage development. In light of this, in the current study we aimed to examine whether gut inflammation, assessed by F-calprotectin, is associated with more structural spinal damage in axSpA. Methods: Patients with well-characterized non-radiographic or radiographic axSpA (nr-axSpA/r-axSpA; n = 76/152), according to ASAS or modified New York criteria, enrolled in a population-based cohort study in southern Sweden, were assessed for structural spinal damage (modified Stoke ankylosing spondylitis spinal score [mSASSS]) and gut inflammation (F-calprotectin). mSASSS values were compared between patients with normal (< 50 mg/kg), moderately elevated (50–149 mg/kg) or distinctly elevated (≥ 150 mg/kg) F-calprotectin, reflecting no/some/evident gut inflammation, respectively (one-way ANOVA). Moreover, logistic regression was applied to explore if elevated F-calprotectin (≥ 50 mg/kg) was associated with mSASSS values above the median, adjusted for sex, symptom duration, HLA-B27 status, smoking, CRP, NSAID and anti-TNF therapy. Analyses limited to r-axSpA were also performed. Results: In both axSpA patients overall and separately in r-axSpA, mSASSS distributions differed significantly between subjects with normal/moderately/distinctly elevated F-calprotectin, with more damage observed in those with higher F-calprotectin levels. Furthermore, elevated F-calprotectin (≥ 50 mg/kg) was associated with mSASSS values above the median, in both the entire axSpA group (adjusted odds ratio [OR] 2.2 [95%CI 1.1–4.2]); and in r-axSpA alone (adjusted OR 2.9 [1.2–7.1]). Conclusion: In the current study, the presence of gut inflammation, assessed by F-calprotectin, was cross-sectionally associated with more structural damage in the spine in patients with axSpA, even after adjustments for known risk factors for spinal damage. Prospective studies are, however, needed to investigate whether gut inflammation may be a predictor of spinal radiographic progression in axSpA.
- 21 October 2025
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 27 (1) , 1-9
Open AccessGut inflammation is associated with structural spinal damage in axial spondyloarthritis – results from the observational SPARTAKUS cohort
Background: In axial spondyloarthritis (axSpA), 5–10% of patients have comorbid inflammatory bowel disease (IBD). Beyond that, 50–60% display histologic inflammation in ileum/colon biopsies, and fecal calprotectin (F-calprotectin) is elevated in relation to healthy controls. Prior studies have shown such, often subclinical, gut inflammation in axSpA to be associated with more active disease, as measured by clinical indices as well as magnetic resonance imaging – both known risk factors for structural spinal damage development. In light of this, in the current study we aimed to examine whether gut inflammation, assessed by F-calprotectin, is associated with more structural spinal damage in axSpA. Methods: Patients with well-characterized non-radiographic or radiographic axSpA (nr-axSpA/r-axSpA; n = 76/152), according to ASAS or modified New York criteria, enrolled in a population-based cohort study in southern Sweden, were assessed for structural spinal damage (modified Stoke ankylosing spondylitis spinal score [mSASSS]) and gut inflammation (F-calprotectin). mSASSS values were compared between patients with normal (< 50 mg/kg), moderately elevated (50–149 mg/kg) or distinctly elevated (≥ 150 mg/kg) F-calprotectin, reflecting no/some/evident gut inflammation, respectively (one-way ANOVA). Moreover, logistic regression was applied to explore if elevated F-calprotectin (≥ 50 mg/kg) was associated with mSASSS values above the median, adjusted for sex, symptom duration, HLA-B27 status, smoking, CRP, NSAID and anti-TNF therapy. Analyses limited to r-axSpA were also performed. Results: In both axSpA patients overall and separately in r-axSpA, mSASSS distributions differed significantly between subjects with normal/moderately/distinctly elevated F-calprotectin, with more damage observed in those with higher F-calprotectin levels. Furthermore, elevated F-calprotectin (≥ 50 mg/kg) was associated with mSASSS values above the median, in both the entire axSpA group (adjusted odds ratio [OR] 2.2 [95%CI 1.1–4.2]); and in r-axSpA alone (adjusted OR 2.9 [1.2–7.1]). Conclusion: In the current study, the presence of gut inflammation, assessed by F-calprotectin, was cross-sectionally associated with more structural damage in the spine in patients with axSpA, even after adjustments for known risk factors for spinal damage. Prospective studies are, however, needed to investigate whether gut inflammation may be a predictor of spinal radiographic progression in axSpA.
- Open Access
- 8 October 2025
- Published by Taylor & Francis in Scandinavian Journal of Rheumatology
- Vol. 54 (6) , 399-411
Validity and reliability of the Danish and Swedish versions of the Bristol Rheumatoid Arthritis Fatigue Questionnaires in patients with spondyloarthritis
To investigate the validity, reliability, and interpretability of the Danish and Swedish versions of the Bristol Rheumatoid Arthritis Fatigue Multi-Dimensional Questionnaire (BRAF-MDQ) and Bristol Rheumatoid Arthritis Fatigue Numerical Rating Scales (BRAF-NRS V2) (BRAFs) in patients with spondyloarthritis (SpA). The BRAFs were tested for validity and reliability in an online survey. Participants were identified in the national rheumatology databases. In Denmark, 234/435 participants (53.8%) completed the first survey (T1), of whom 125 (82.2%) also completed the second survey (T2) (mean ± sd age 59.6 ± 13 years, 52.6% women). In Sweden, 183/420 participants (43.6%) completed T1, of whom 171 (93.4%) also completed T2 (age 54.7 ± 13 years, 62.3% female). In both Denmark and Sweden, the content validity was supported for the BRAFs; regarding structural validity for BRAF-MDQ, explanatory factor analysis identified five factors; Cronbach's α (internal consistency) was 0.94/0.95 for BRAF-MDQ and 0.79-0.93/0.76-0.94 for the four subscales; intraclass correlation coefficients (ICCs) were 0.96/0.93 for BRAF-MDQ and 0.84-0.93/0.86-0.90 for the subscales, and ICCs of the three BRAF-NRS scales were 0.70-0.90/0.71-0.89; and Construct validity: 80% of the hypotheses were fulfilled for the BRAFs. Good content validity, acceptable construct validity, good reliability, and low degree of measurement error were found for BRAF-MDQ and BRAF-NRS V2. BRAF-MDQ had acceptable structural validity, but five factors were identified, instead of four, suggesting caution in distinguishing dimensions of fatigue. The BRAFs are considered valid and reliable for measuring fatigue in Danish and Swedish patients with SpA.
- 8 October 2025
- Published by Taylor & Francis in Scandinavian Journal of Rheumatology
- Vol. 54 (6) , 399-411
Open AccessValidity and reliability of the Danish and Swedish versions of the Bristol Rheumatoid Arthritis Fatigue Questionnaires in patients with spondyloarthritis
To investigate the validity, reliability, and interpretability of the Danish and Swedish versions of the Bristol Rheumatoid Arthritis Fatigue Multi-Dimensional Questionnaire (BRAF-MDQ) and Bristol Rheumatoid Arthritis Fatigue Numerical Rating Scales (BRAF-NRS V2) (BRAFs) in patients with spondyloarthritis (SpA). The BRAFs were tested for validity and reliability in an online survey. Participants were identified in the national rheumatology databases. In Denmark, 234/435 participants (53.8%) completed the first survey (T1), of whom 125 (82.2%) also completed the second survey (T2) (mean ± sd age 59.6 ± 13 years, 52.6% women). In Sweden, 183/420 participants (43.6%) completed T1, of whom 171 (93.4%) also completed T2 (age 54.7 ± 13 years, 62.3% female). In both Denmark and Sweden, the content validity was supported for the BRAFs; regarding structural validity for BRAF-MDQ, explanatory factor analysis identified five factors; Cronbach's α (internal consistency) was 0.94/0.95 for BRAF-MDQ and 0.79-0.93/0.76-0.94 for the four subscales; intraclass correlation coefficients (ICCs) were 0.96/0.93 for BRAF-MDQ and 0.84-0.93/0.86-0.90 for the subscales, and ICCs of the three BRAF-NRS scales were 0.70-0.90/0.71-0.89; and Construct validity: 80% of the hypotheses were fulfilled for the BRAFs. Good content validity, acceptable construct validity, good reliability, and low degree of measurement error were found for BRAF-MDQ and BRAF-NRS V2. BRAF-MDQ had acceptable structural validity, but five factors were identified, instead of four, suggesting caution in distinguishing dimensions of fatigue. The BRAFs are considered valid and reliable for measuring fatigue in Danish and Swedish patients with SpA.
- Open Access
- 1 September 2025
- Published by Taylor & Francis in Scandinavian Journal of Rheumatology
- Vol. 54 (6) , 421-433
Known and less well-known comorbidities in axial spondyloarthritis: what are we overlooking? Results from the SPARTAKUS cohort
To explore and compare the prevalences of a wide range of comorbidities in axial spondyloarthritis (axSpA) versus the general population, and in non-radiographic versus radiographic axSpA (nr-axSpA/r-axSpA). Well-characterized axSpA patients (n = 246) from the SPARTAKUS cohort (55% men; mean age/disease duration 52/26 years; nr-axSpA/r-axSpA = 82/164) were included, and matched to comparators from the general population (five/patient) randomly drawn from the Swedish Population Register. Fifty-nine comorbidities were determined from ICD-10 diagnosis registrations in primary/specialized care, with data retrieved for the 10 year period preceding SPARTAKUS inclusion (for patients/their respective comparators). Differences in comorbidity prevalences were analyzed using logistic regression and controlled for multiple comparisons. Most investigated comorbidities were numerically overrepresented in axSpA versus comparators with significantly higher prevalences of known extra-musculoskeletal manifestations [anterior uveitis (28% vs 1%), IBD (10%/1%), psoriasis (10%/3%)], and ischaemic heart disease (7%/3%), along with less explored conditions such as fibromyalgia/chronic pain (12%/3%) and nephrolithiasis (8%/3%). Patients displayed significantly higher proportions of well-known side-effects of non-steroidal anti-inflammatory drugs (NSAIDs) [gastritis (21%/10%), hypertension (31%/19%)] and glucocorticoids [cataract (11%/7%), glaucoma (7%/3%), osteoporosis/vertebral compression (4%/1%)]. No significant between-group difference (patients/comparators) was observed for Charlson Comorbidity Index (assessing short-term mortality risk) when excluding rheumatic disease. Moreover, no significant difference in comorbidity was found between nr-axSpA and r-axSpA. axSpA is linked to several comorbidities, whereas no difference was observed between nr-axSpA and r-axSpA. Potential causes of enhanced comorbidity include long-standing inflammation and therapy side-effects (including from NSAIDs/glucocorticoids), both to be considered when aiming to optimize axSpA treatment.
- 1 September 2025
- Published by Taylor & Francis in Scandinavian Journal of Rheumatology
- Vol. 54 (6) , 421-433
Open AccessKnown and less well-known comorbidities in axial spondyloarthritis: what are we overlooking? Results from the SPARTAKUS cohort
To explore and compare the prevalences of a wide range of comorbidities in axial spondyloarthritis (axSpA) versus the general population, and in non-radiographic versus radiographic axSpA (nr-axSpA/r-axSpA). Well-characterized axSpA patients (n = 246) from the SPARTAKUS cohort (55% men; mean age/disease duration 52/26 years; nr-axSpA/r-axSpA = 82/164) were included, and matched to comparators from the general population (five/patient) randomly drawn from the Swedish Population Register. Fifty-nine comorbidities were determined from ICD-10 diagnosis registrations in primary/specialized care, with data retrieved for the 10 year period preceding SPARTAKUS inclusion (for patients/their respective comparators). Differences in comorbidity prevalences were analyzed using logistic regression and controlled for multiple comparisons. Most investigated comorbidities were numerically overrepresented in axSpA versus comparators with significantly higher prevalences of known extra-musculoskeletal manifestations [anterior uveitis (28% vs 1%), IBD (10%/1%), psoriasis (10%/3%)], and ischaemic heart disease (7%/3%), along with less explored conditions such as fibromyalgia/chronic pain (12%/3%) and nephrolithiasis (8%/3%). Patients displayed significantly higher proportions of well-known side-effects of non-steroidal anti-inflammatory drugs (NSAIDs) [gastritis (21%/10%), hypertension (31%/19%)] and glucocorticoids [cataract (11%/7%), glaucoma (7%/3%), osteoporosis/vertebral compression (4%/1%)]. No significant between-group difference (patients/comparators) was observed for Charlson Comorbidity Index (assessing short-term mortality risk) when excluding rheumatic disease. Moreover, no significant difference in comorbidity was found between nr-axSpA and r-axSpA. axSpA is linked to several comorbidities, whereas no difference was observed between nr-axSpA and r-axSpA. Potential causes of enhanced comorbidity include long-standing inflammation and therapy side-effects (including from NSAIDs/glucocorticoids), both to be considered when aiming to optimize axSpA treatment.
- Open Access
- 27 June 2024
- Published by Springer Nature in BMC Rheumatology
- Vol. 8 (1) , 1-9
Belonging, happiness, freedom and empowerment—a qualitative study of patients’ understanding of health in early rheumatoid arthritis
Background: Rheumatoid arthritis (RA) is a chronic, systemic, inflammatory joint disease, that influences patients’ health in different ways, including physical, social, emotional, and psychological aspects. The goal of rheumatology care is to achieve optimal health and personalised care and therefore, it is essential to understand what health means for patients in the early course of RA. The aim of this study was to describe the understanding of health among patients with early RA. Methods: The study had a descriptive qualitative design with a phenomenographic approach. Phenomenography is used to analyse, describe, and understand various ways people understand or experience a phenomenon, in this study, patients’ understandings of health. Individual semi-structured interviews were conducted with 31 patients (22 women and nine men, aged (38–80) with early RA, defined as a disease duration of < 1 year, and disease-modifying anti-rheumatic drugs (DMARDs) for 3–7 months. The phenomenographic analysis was conducted in 7 steps, and the outcome space presents the variation in understanding and the interrelation among categories. In accordance with the European Alliance of Associations for Rheumatology’s (EULAR) recommendations, a patient research partner participated in all phases of the study. Results: The analysis revealed four main descriptive categories: ‘Health as belonging’ was described as experiencing a sense of coherence. ‘Health as happiness’ was understood as feeling joy in everyday life. ‘Health as freedom’ was understood as feeling independent. ‘Health as empowerment’ was understood as feeling capable. Essential health aspects in early RA are comprised of a sense of coherence, joy, independence, and the capability to manage everyday life. Conclusions: This study revealed that patients’ perception of health in early RA encompasses various facets, including a sense of belonging, happiness, freedom, and empowerment. It highlighted that health is multifaceted and personal, emphasizing the importance of acknowledging this diversity in providing person-centred care. The findings can guide healthcare professionals to deepen patients’ participation in treatment goals, which may lead to better treatment adherence and health outcomes.
- 27 June 2024
- Published by Springer Nature in BMC Rheumatology
- Vol. 8 (1) , 1-9
Open AccessBelonging, happiness, freedom and empowerment—a qualitative study of patients’ understanding of health in early rheumatoid arthritis
Background: Rheumatoid arthritis (RA) is a chronic, systemic, inflammatory joint disease, that influences patients’ health in different ways, including physical, social, emotional, and psychological aspects. The goal of rheumatology care is to achieve optimal health and personalised care and therefore, it is essential to understand what health means for patients in the early course of RA. The aim of this study was to describe the understanding of health among patients with early RA. Methods: The study had a descriptive qualitative design with a phenomenographic approach. Phenomenography is used to analyse, describe, and understand various ways people understand or experience a phenomenon, in this study, patients’ understandings of health. Individual semi-structured interviews were conducted with 31 patients (22 women and nine men, aged (38–80) with early RA, defined as a disease duration of < 1 year, and disease-modifying anti-rheumatic drugs (DMARDs) for 3–7 months. The phenomenographic analysis was conducted in 7 steps, and the outcome space presents the variation in understanding and the interrelation among categories. In accordance with the European Alliance of Associations for Rheumatology’s (EULAR) recommendations, a patient research partner participated in all phases of the study. Results: The analysis revealed four main descriptive categories: ‘Health as belonging’ was described as experiencing a sense of coherence. ‘Health as happiness’ was understood as feeling joy in everyday life. ‘Health as freedom’ was understood as feeling independent. ‘Health as empowerment’ was understood as feeling capable. Essential health aspects in early RA are comprised of a sense of coherence, joy, independence, and the capability to manage everyday life. Conclusions: This study revealed that patients’ perception of health in early RA encompasses various facets, including a sense of belonging, happiness, freedom, and empowerment. It highlighted that health is multifaceted and personal, emphasizing the importance of acknowledging this diversity in providing person-centred care. The findings can guide healthcare professionals to deepen patients’ participation in treatment goals, which may lead to better treatment adherence and health outcomes.
- Open Access
Are JAKis more effective among elderly patients with RA, smokers and those with higher cardiovascular risk? A comparative effectiveness study of b/tsDMARDs in Sweden
Objectives To investigate whether the relative effectiveness of janus kinase inhibitors (JAKis) versus tumour necrosis factor inhibitors (TNFi) or other biological disease-modifying antirheumatic drugs in rheumatoid arthritis differ by the presence or absence of risk factors for cardiovascular (CV) disease, age, sex and smoking. Methods Through Swedish registers, we identified 13 493 individuals with 3166 JAKi, 5575 non-TNFi and 11 286 TNFi treatment initiations 2016–2022. All lines of therapy were included, with the majority in second line or higher. Treatment response was defined as the proportion reaching European Alliance of Associations for Rheumatology (EULAR) good response and Clinical Disease Activity Index (CDAI) remission, respectively, within 6 months. Crude percentage point differences in these proportions (JAKis, and non-TNFis, vs TNFis) overall and by risk factors were observed, and adjusted for confounders using linear regression models. Predicted probabilities of response and remission were estimated from adjusted Poisson models, and presented across CV risk and age. Results Overall, adjusted percentage point differences indicated higher response (+5.0%, 95% CI 2.2% to 7.9%) and remission (+5.8%, 95% CI 3.2% to 8.5%) with JAKis versus TNFis. The adjusted percentage point differences for response in those above 65, at elevated CV risk, and smokers were +5.9% (95% CI 2.7% to 9.0%), +8.3% (95% CI 5.3% to 11.4%) and +6.0% (95% CI 3.3% to 8.7%), respectively. The corresponding estimates for remission were +8.0% (95% CI 5.3% to 10.8%), +5.6% (95% CI 3.0% to 8.2%) and +7.6% (95% CI 5.5% to 9.7%). Conclusions As used in clinical practice, response and remission at 6 months with JAKis are higher than with TNFi. Among patients with risk factors of concern, effectiveness is similar or numerically further increased. For individualised benefit-to-risk ratios to guide treatment choice, safety and effectiveness in specific patient segments should be considered.
Open AccessAre JAKis more effective among elderly patients with RA, smokers and those with higher cardiovascular risk? A comparative effectiveness study of b/tsDMARDs in Sweden
Objectives To investigate whether the relative effectiveness of janus kinase inhibitors (JAKis) versus tumour necrosis factor inhibitors (TNFi) or other biological disease-modifying antirheumatic drugs in rheumatoid arthritis differ by the presence or absence of risk factors for cardiovascular (CV) disease, age, sex and smoking. Methods Through Swedish registers, we identified 13 493 individuals with 3166 JAKi, 5575 non-TNFi and 11 286 TNFi treatment initiations 2016–2022. All lines of therapy were included, with the majority in second line or higher. Treatment response was defined as the proportion reaching European Alliance of Associations for Rheumatology (EULAR) good response and Clinical Disease Activity Index (CDAI) remission, respectively, within 6 months. Crude percentage point differences in these proportions (JAKis, and non-TNFis, vs TNFis) overall and by risk factors were observed, and adjusted for confounders using linear regression models. Predicted probabilities of response and remission were estimated from adjusted Poisson models, and presented across CV risk and age. Results Overall, adjusted percentage point differences indicated higher response (+5.0%, 95% CI 2.2% to 7.9%) and remission (+5.8%, 95% CI 3.2% to 8.5%) with JAKis versus TNFis. The adjusted percentage point differences for response in those above 65, at elevated CV risk, and smokers were +5.9% (95% CI 2.7% to 9.0%), +8.3% (95% CI 5.3% to 11.4%) and +6.0% (95% CI 3.3% to 8.7%), respectively. The corresponding estimates for remission were +8.0% (95% CI 5.3% to 10.8%), +5.6% (95% CI 3.0% to 8.2%) and +7.6% (95% CI 5.5% to 9.7%). Conclusions As used in clinical practice, response and remission at 6 months with JAKis are higher than with TNFi. Among patients with risk factors of concern, effectiveness is similar or numerically further increased. For individualised benefit-to-risk ratios to guide treatment choice, safety and effectiveness in specific patient segments should be considered.
- Open Access
- 30 November 2023
- Published by Taylor & Francis in Scandinavian Journal of Rheumatology
- Vol. 53 (2) , 94-103
Persistent pain and its predictors after starting anti-tumour necrosis factor therapy in psoriatic arthritis: what is the role of inflammation control?
While considerable focus has been placed on pain due to inflammation in psoriatic arthritis (PsA), less is reported on pain despite inflammation control. Here, we aimed to investigate the occurrence/predictors of persistent pain, including non-inflammatory components, after starting anti-tumour necrosis factor (anti-TNF) therapy. Bionaïve PsA patients starting a first anti-TNF therapy 2004-2010 were identified (South Swedish Arthritis Treatment Group register; N = 351). Outcomes included unacceptable pain [visual analogue scale (VAS) pain > 40 mm], and unacceptable pain despite inflammation control (refractory pain; VAS pain > 40 mm + C-reactive protein < 10 mg/L + ≤ 1 swollen joint of 28), assessed at 0, 3, 6, and 12 months. Baseline predictors were estimated by logistic regression. Upon starting anti-TNF therapy, 85% of patients reported unacceptable pain, falling to 43% at 3 months and then remaining stable. After 12 months, refractory pain constituted 63% of all unacceptable pain. Higher baseline VAS pain/global, worse physical function and lower health-related quality-of-life were associated with a higher risk of unacceptable/refractory pain at 12 months. More swollen joints and higher evaluator's global assessment were associated with a lower risk of 12-month refractory pain. A substantial proportion of PsA patients reported unacceptable pain throughout the first anti-TNF treatment year. At 12 months, refractory pain constituted about two-thirds of this remaining pain load. More objective signs of inflammation at anti-TNF initiation were associated with less future refractory pain. This highlights insufficient effect of biologics in patients with inflammation-independent pain, warranting alternative treatments.
- 30 November 2023
- Published by Taylor & Francis in Scandinavian Journal of Rheumatology
- Vol. 53 (2) , 94-103
Open AccessPersistent pain and its predictors after starting anti-tumour necrosis factor therapy in psoriatic arthritis: what is the role of inflammation control?
While considerable focus has been placed on pain due to inflammation in psoriatic arthritis (PsA), less is reported on pain despite inflammation control. Here, we aimed to investigate the occurrence/predictors of persistent pain, including non-inflammatory components, after starting anti-tumour necrosis factor (anti-TNF) therapy. Bionaïve PsA patients starting a first anti-TNF therapy 2004-2010 were identified (South Swedish Arthritis Treatment Group register; N = 351). Outcomes included unacceptable pain [visual analogue scale (VAS) pain > 40 mm], and unacceptable pain despite inflammation control (refractory pain; VAS pain > 40 mm + C-reactive protein < 10 mg/L + ≤ 1 swollen joint of 28), assessed at 0, 3, 6, and 12 months. Baseline predictors were estimated by logistic regression. Upon starting anti-TNF therapy, 85% of patients reported unacceptable pain, falling to 43% at 3 months and then remaining stable. After 12 months, refractory pain constituted 63% of all unacceptable pain. Higher baseline VAS pain/global, worse physical function and lower health-related quality-of-life were associated with a higher risk of unacceptable/refractory pain at 12 months. More swollen joints and higher evaluator's global assessment were associated with a lower risk of 12-month refractory pain. A substantial proportion of PsA patients reported unacceptable pain throughout the first anti-TNF treatment year. At 12 months, refractory pain constituted about two-thirds of this remaining pain load. More objective signs of inflammation at anti-TNF initiation were associated with less future refractory pain. This highlights insufficient effect of biologics in patients with inflammation-independent pain, warranting alternative treatments.
- Open Access
- 27 July 2023
- Published by Taylor & Francis in International Journal of Qualitative Studies on Health and Well-being
- Vol. 18 (1) , 2241225
Healthcare professionals’ perceptions of working on lifestyle management for patients with early rheumatoid arthritis — a qualitative study
To explore HPs’ perceptions of working on lifestyle management for patients with early rheumatoid arthritis (RA). In this qualitative study, individual interviews were conducted with 20 HPs. Qualitative content analysis was used, and three categories and six subcategories were identified. HPs’ perceptions of working on lifestyle management for patients with early RA revealed a need for commitment from different levels. This included commitment from healthcare managers and organizations prioritizing work on lifestyle management and providing competence development for HPs. Commitment within the team regarding coordination of interdisciplinary teamwork and development of a structured lifestyle management approach, and commitment to involving patients in lifestyle management, by facilitating patient engagement and a person-centred approach. HPs’ perceptions of working on lifestyle management for patients with early RA revealed that commitment from healthcare managers, organizations, and the interdisciplinary team was essential to facilitate collaboration, patient involvement, and a person-centred approach.
- 27 July 2023
- Published by Taylor & Francis in International Journal of Qualitative Studies on Health and Well-being
- Vol. 18 (1) , 2241225
Open AccessHealthcare professionals’ perceptions of working on lifestyle management for patients with early rheumatoid arthritis — a qualitative study
To explore HPs’ perceptions of working on lifestyle management for patients with early rheumatoid arthritis (RA). In this qualitative study, individual interviews were conducted with 20 HPs. Qualitative content analysis was used, and three categories and six subcategories were identified. HPs’ perceptions of working on lifestyle management for patients with early RA revealed a need for commitment from different levels. This included commitment from healthcare managers and organizations prioritizing work on lifestyle management and providing competence development for HPs. Commitment within the team regarding coordination of interdisciplinary teamwork and development of a structured lifestyle management approach, and commitment to involving patients in lifestyle management, by facilitating patient engagement and a person-centred approach. HPs’ perceptions of working on lifestyle management for patients with early RA revealed that commitment from healthcare managers, organizations, and the interdisciplinary team was essential to facilitate collaboration, patient involvement, and a person-centred approach.